ABVC BioPharma, Inc.(ABVC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ABVC ABVC BioPharma, Inc.

Market Closed 12-20 16:00:00 EST

0.5240

+0.0063

+1.22%

盘后0.5003

-0.0237-4.52%

17:46 EST

High0.5300	Low0.4900	Vol100.03K
Open0.5080	D1 Closing0.5177	Amplitude7.73%
Mkt Cap6.80M	Tradable Cap5.31M	Total Shares12.98M
T/O50.91K	T/O Rate0.99%	Tradable Shares10.13M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"ABVC","market":"US","secType":"STK","nameCN":"ABVC BioPharma, Inc.","latestPrice":0.524,"timestamp":1734728400000,"preClose":0.5177,"halted":0,"volume":100034,"hourTrading":{"tag":"盘后","latestPrice":0.5003,"preClose":0.524,"latestTime":"17:46 EST","volume":1221,"amount":634.8299,"timestamp":1734734797692},"delay":0,"floatShares":10127000,"shares":12975492,"eps":-0.824102,"marketStatus":"Market Closed","change":0.0063,"latestTime":"12-20 16:00:00 EST","open":0.508,"high":0.53,"low":0.49,"amount":50909.183239,"amplitude":0.077265,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.824102,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1734944400000},"marketStatusCode":7,"adr":0,"listingDate":1627963200000,"exchange":"NASDAQ","adjPreClose":0.5177,"preHourTrading":{"tag":"盘前","latestPrice":0.508,"preClose":0.5177,"latestTime":"08:47 EST","volume":1539,"amount":784.482242,"timestamp":1734702427636},"postHourTrading":{"tag":"盘后","latestPrice":0.5003,"preClose":0.524,"latestTime":"17:46 EST","volume":1221,"amount":634.8299,"timestamp":1734734797692},"volumeRatio":0.6656203549492556},"requestUrl":"/m/hq/s/ABVC/wiki","defaultTab":"wiki","newsList":[{"id":"2492517061","title":"MIRA Pharmaceuticals Submits IND for Ketamir-2 to FDA, Marking a Significant Milestone in the Company's Pipeline Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2492517061","media":"ACCESSWIRE","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492517061?lang=en_us&edition=fundamental","pubTime":"2024-12-19 22:00","pubTimestamp":1734616800,"startTime":"0","endTime":"0","summary":"MIAMI, FL / ACCESSWIRE / December 19, 2024 / MIRA Pharmaceuticals, Inc. , a preclinical-stage pharmaceutical company focused on developing therapies for neurological and neuropsychiatric disorders, today announced that it has submitted an Investigational New Drug  application to the U.S. Food and Drug Administration  for Ketamir-2, its novel oral ketamine analog for the treatment of neuropathic pain. The IND submission marks a major step in advancing Mira's lead drug candidate while reflecting its commitment to meeting milestones and timelines.Ketamir-2 is specifically designed to address the limitations of existing treatments through its selective targeting of the NMDA receptor. By binding to a specific site on the NMDA receptor with low affinity, Ketamir-2 significantly reduces the risk of psychotropic effects commonly associated with traditional ketamine. Furthermore, it is not a substrate for P-glycoprotein , which allows for better oral absorption and enhanced blood-brain barrier ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mira-pharmaceuticals-submits-ind-ketamir-140000120.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","BK4159","MIRA","BK4139","ABVC","CAGR"],"gpt_icon":0},{"id":"2492317479","title":"Jaguar Health Announces Import of Coca Leaf From Peru by Joint Venture Magdalena Biosciences for Research in Treating Mental Health Indications","url":"https://stock-news.laohu8.com/highlight/detail?id=2492317479","media":"ACCESSWIRE","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492317479?lang=en_us&edition=fundamental","pubTime":"2024-12-19 22:00","pubTimestamp":1734616800,"startTime":"0","endTime":"0","summary":"Magdalena to explore coca leaf's possible therapeutic benefit for treatment of potentially ADHD or other neuropsychiatric indications. The import was conducted in collaboration with the government of Peru. Steven King, Ph.D. of Jaguar to speak about the potential promise of coca-based Botanical Drugs at the February 2025 Wisdom of the Leaf Coca Summit in Peru. Magdalena is focused on developing novel, natural prescription medicines derived from plants for mental health indications. \"We are pleased to partner with Filament Health and Magdalena to facilitate this second import of coca leaf,\" said Silveria Dongo Gonzales, Technical Director of ENACO. \"We appreciate Filament and Magdalena's diligent efforts in maintaining a productive relationship with ENACO.\". \"By importing this significant volume of raw material, we are able to begin the important work of exploring coca leaf's therapeutic potential for the treatmen","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/q5.go9g5djaUPSAziewZdg--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/03d985faeafe92d1dfe136f95351426f","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/q5.go9g5djaUPSAziewZdg--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/03d985faeafe92d1dfe136f95351426f"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/jaguar-health-announces-import-coca-140000278.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","BK4139","ABVC","FLHLF","JAGX","JYNT","BK4185","ADHD"],"gpt_icon":0},{"id":"2492848178","title":"ABVC Biopharma Seeks to Revolutionize Mental Health Treatment With a Safe Prozac Alternative, Boasting a Madrs Score Reduction of -13.21","url":"https://stock-news.laohu8.com/highlight/detail?id=2492848178","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492848178?lang=en_us&edition=fundamental","pubTime":"2024-12-19 21:30","pubTimestamp":1734615002,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241219:nTUABYYWFX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ABVC"],"gpt_icon":0},{"id":"2492417896","title":"ABVC BioPharma Seeks to Revolutionize Mental Health Treatment With a Safe Prozac Alternative, Boasting a MADRS Score Reduction of -13.21","url":"https://stock-news.laohu8.com/highlight/detail?id=2492417896","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492417896?lang=en_us&edition=fundamental","pubTime":"2024-12-19 21:30","pubTimestamp":1734615000,"startTime":"0","endTime":"0","summary":"FREMONT, Calif., Dec.  19, 2024  (GLOBE NEWSWIRE) -- ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company focused on innovative treatments in ophthalmology, CNS (central ner","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/19/2999864/0/en/ABVC-BioPharma-Seeks-to-Revolutionize-Mental-Health-Treatment-With-a-Safe-Prozac-Alternative-Boasting-a-MADRS-Score-Reduction-of-13-21.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADHD","BK4139","PHH","WRD","ABVC"],"gpt_icon":0},{"id":"2492837271","title":"Alzamend Neuro to Present Non-Clinical Data Update at the Society of Toxicology 2025 Annual Meeting and ToxExpo","url":"https://stock-news.laohu8.com/highlight/detail?id=2492837271","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492837271?lang=en_us&edition=fundamental","pubTime":"2024-12-18 21:00","pubTimestamp":1734526800,"startTime":"0","endTime":"0","summary":"Presentation Topic is the Pharmacokinetics of AL001, a Lithium Salicylate/L-Proline Co-crystal, as a Potentially Beneficial Lithium Sparing Treatment for Bipolar Disorder Type 1, Alzheimer’s Disease, Major Depressive Disorder and Post-Traumatic Stress Disorder. ATLANTA, December 18, 2024----Alzamend Neuro, Inc.  , a clinical-stage biopharmaceutical company, focused on developing novel products for the treatment of Alzheimer’s disease , bipolar disorder , major depressive disorder  and post-traumatic stress disorder , today announced it will have a poster presentation at the Society of Toxicology  Annual Meeting and ToxExpo, being held from March 16-20, 2025, in Orlando, Florida.Summary: No Undue Adverse Effects: Both treatments had no negative impact on the mice's body weight or clinical signs during the treatment period. Reduced Systemic Exposure: AL001 showed lower plasma lithium levels than lithium carbonate, reducing the risk of adverse systemic effects, suggesting an expansion for","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/kakA41MLk0x_m0FhpQPdKQ--~B/aD0zNDY7dz0xNjY3O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/c10ae0696b6c771841f4f21f6a637362","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/kakA41MLk0x_m0FhpQPdKQ--~B/aD0zNDY7dz0xNjY3O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/c10ae0696b6c771841f4f21f6a637362"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/alzamend-neuro-present-non-clinical-130000496.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","ALZN","ABVC"],"gpt_icon":0},{"id":"2492628058","title":"Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2492628058","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492628058?lang=en_us&edition=fundamental","pubTime":"2024-12-17 05:30","pubTimestamp":1734384600,"startTime":"0","endTime":"0","summary":"MALVERN, Pa., Dec.  16, 2024  (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company”) today announced the granting of inducement awards to new employees as described below. In accordance ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/16/2997903/0/en/Neuronetics-Reports-Inducement-Grant-Under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","LU2095319765.USD","BK4588","BK4139","BK4112","IE00BKPKM429.USD","ABVC","LU2210149790.SGD","PHH","LU2210150020.SGD","IE00B3QW5Z07.USD","STIM","WRD","BK4585","NDAQ","BK4082",".IXIC","IE00B64PRP62.GBP"],"gpt_icon":0},{"id":"2492230466","title":"Knight Therapeutics Announces Filing of New Drug Submission for Qelbree® (viloxazine) in Canada","url":"https://stock-news.laohu8.com/highlight/detail?id=2492230466","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492230466?lang=en_us&edition=fundamental","pubTime":"2024-12-17 05:30","pubTimestamp":1734384600,"startTime":"0","endTime":"0","summary":"MONTREAL, Dec. 16, 2024  -- Knight Therapeutics Inc.  , a pan-American  specialty pharmaceutical company, announced today that Knight's New Drug Submission  for Qelbree  has been accepted for review by Health Canada. Qelbree is a novel nonstimulant medication for the treatment of Attention-Deficit Hyperactivity Disorder .Knight entered into an agreement in December 2023 with Supernus Pharmaceuticals, Inc.  for the exclusive rights to commercialize Qelbree in Canada. Qelbree is commercially available in the United States as a prescription medicine to treat ADHD in patients 6 years of age and older. Based on the results of 4 pivotal trials,1-4 Qelbree was approved by the US Food and Drug Administration in April 2021 for the treatment of ADHD in children 6-17 years of age and in April 2022 for the treatment of ADHD in adults.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/CaqJKaOolmtgJE2W6pfMNw--~B/aD0yNTc7dz05ODI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/6f19f960aa8749173a3ec6cb85899dea","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/CaqJKaOolmtgJE2W6pfMNw--~B/aD0yNTc7dz05ODI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/6f19f960aa8749173a3ec6cb85899dea"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/knight-therapeutics-announces-filing-drug-213000803.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LENZ","BK4007","SUPN","ABVC","ADHD","BK4139"],"gpt_icon":0},{"id":"2491660644","title":"FILAMENT HEALTH ANNOUNCES IMPORT OF COCA LEAF FROM PERU BY JOINT VENTURE MAGDALENA BIOSCIENCES","url":"https://stock-news.laohu8.com/highlight/detail?id=2491660644","media":"CNW Group","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491660644?lang=en_us&edition=fundamental","pubTime":"2024-12-16 20:00","pubTimestamp":1734350400,"startTime":"0","endTime":"0","summary":"The import was conducted in collaboration with the government of Peru. VANCOUVER, BC, Dec. 16, 2024 /CNW/ -Filament Health Corp.    , a clinical-stage natural psychedelic drug development company, today announced that Magdalena Biosciences , a joint venture formed by Filament and Jaguar Health, Inc.  , successfully completed an import of six kilograms of coca leaf from Peru to Filament's Metro Vancouver research and development facility. This is the second import of coca leaf that Magdalena has completed. It was authorized by the Peruvian Health Authority, Dirección General de Medicamentos Insumos y Drogas , and acquired from the Empresa Nacional de la Coca , the only company in Peru authorized to distribute coca leaf.ABOUT FILAMENT HEALTH   Filament Health is a clinical-stage natural psychedelic drug development company. We believe that safe, standardized, naturally-derived psychedelic medicines can improve the lives of many, and our mission is to see them in the hands of everyone who","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/XUcYoC5JtFL5o30AXTe88A--~B/aD0xMjY7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/cnwgroup.com/0dc31c9e0d3a99e7d8411ad3e21c9467","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/XUcYoC5JtFL5o30AXTe88A--~B/aD0xMjY7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/cnwgroup.com/0dc31c9e0d3a99e7d8411ad3e21c9467"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/filament-health-announces-import-coca-120000634.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","ADHD","LEAF","BK4007","ABVC","JAGX","BK4211","BY","JYNT","FLHLF","BK4185"],"gpt_icon":0},{"id":"2491227517","title":"The Drugs Young Bankers Use to Get Through the Day -- and Night -- WSJ","url":"https://stock-news.laohu8.com/highlight/detail?id=2491227517","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491227517?lang=en_us&edition=fundamental","pubTime":"2024-12-15 10:00","pubTimestamp":1734228000,"startTime":"0","endTime":"0","summary":"As Mark Moran was facing another 90-hour week as an investment-banking intern at Credit Suisse in New York, he knew he needed help to survive the rest of the summer. His colleagues gave him a tip: Visit a Wall Street health clinic and tell the staff he had trouble focusing.Ahead of his first appointment, he filled out a five-minute questionnaire. One of the questions asked if he had trouble staying organized, another, if he procrastinated. He then met with a clinician who said his answers suggested he had attention-deficit hyperactivity disorder. He left with a prescription for Adderall.No matter that a family member, a psychologist, didn't think Moran had ADHD. He found that when he took Adderall, he could keep working for hours, and was able to actually be interested in some of the mundane tasks required of a young investment banker, such as aligning corporate logos on a PowerPoint or formatting cells in Microsoft Excel.A Wall Street Journal investigation in August about Bank of Amer","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4592","IE00BHPRN162.USD","IE00BN29S564.USD","LU1121112475.USD","LU0124676726.USD","LU0861579265.USD","LU2552382058.USD","LU1989772840.SGD","LU2404859741.USD","SG9999001077.SGD","LU0048584097.USD","SG9999014575.USD","LU0882574139.USD","LU1236620834.HKD","IE00BFXG0V08.USD","LU2023250504.SGD","LU2360032135.SGD","IE00B775SV38.USD","BK4097","LU1043141123.HKD","LU2506952097.USD","SG9999014906.USD","LU0251132253.USD","BK4504","LU1228905540.USD","ABVC","LU1868837136.USD","SG9999014559.SGD","LU0289961442.SGD","LU0127658192.USD","LU2458330169.SGD","LU2430703095.HKD","LU0879622024.SGD","LU1069344957.HKD","LU0708995401.HKD","LU1823568750.SGD","LU2360108059.USD","LU0511384066.AUD","LU0787776722.HKD","LU2237443622.USD","LU0056508442.USD","LU1721428933.USD","LU1548497426.USD","LU2271345857.HKD","LU2461242641.AUD","SG9999001424.SGD","LU1712237335.SGD","SG9999004303.SGD","IE00BDRTCR15.USD"],"gpt_icon":1},{"id":"2490881563","title":"Press Release: Alzamend Neuro Reports Second Quarter 2025 Financial Results and Provides Update on Clinical Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2490881563","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490881563?lang=en_us&edition=fundamental","pubTime":"2024-12-12 21:00","pubTimestamp":1734008400,"startTime":"0","endTime":"0","summary":"During the six months ended October 31, 2024, net cash provided by. Stockholder equity of $3.8 million at October 31, 2024, including $4.1. Strengthened balance sheet in preparation for five clinical trials to. \"These financing transactions have allowed us to greatly improve our financial situation,\" said Stephan Jackman, Chief Executive Officer of Alzamend. \"In the first six months of this fiscal year, we have gone from a stockholder deficit to several million in stockholder equity, significantly reduced our outstanding liabilities and increased our cash on hand. These financial improvements allowed us to regain compliance with all applicable requirements for our stock to continue to be listed on Nasdaq and provides us with the capital in preparation of the upcoming clinical trials to be initiated in 2025.\". Alzamend is developing innovative treatments for Alzheimer's, BD, MDD and PTSD. Its leading drug candidate, AL001, utilizes a novel lithium-salicylate/L-p","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVC","BK4139","ALZN"],"gpt_icon":0},{"id":"2490854129","title":"Alto Neuroscience Announces Data Presented at the 63rd Annual Meeting of the American College of Neuropsychopharmacology","url":"https://stock-news.laohu8.com/highlight/detail?id=2490854129","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490854129?lang=en_us&edition=fundamental","pubTime":"2024-12-11 21:03","pubTimestamp":1733922180,"startTime":"0","endTime":"0","summary":"– Data generated from Alto’s precision psychiatry platform and clinical-stage product candidates highlighted across three poster presentations and a panel discussion –。– New preclinical data from a reverse translation study demonstrates the link between the mechanism of ALTO-300 and the EEG biomarker used for patient selection –。– An interim analysis will be conducted for the ongoing Phase 2b trial of ALTO-300 as an adjunctive treatment in MDD; results from the interim analysis are expected in the first quarter of 2025, followed by topline data from the complete study sample in the first half of 2025 –","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/nlv57F6zxTB8SR91fcBKMw--~B/aD01Mzc7dz0xNjU5O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/cb0c9c80f60417ff34072d58865a1f4e","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/nlv57F6zxTB8SR91fcBKMw--~B/aD01Mzc7dz0xNjU5O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/cb0c9c80f60417ff34072d58865a1f4e"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/alto-neuroscience-announces-data-presented-130300504.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0289739699.SGD","BK4139","BK4007","GRO","ANRO","LU1261432733.SGD","IE00B19Z3B42.SGD","CI","IE0002270589.USD","IE00B19Z3581.USD","BK4107","BK4588","IE00BSNM7G36.USD","LU1059921491.USD","BK4117","AFG","BK4196","LU0058720904.USD","BK4585","ABVC","LU0868494617.USD"],"gpt_icon":0},{"id":"2490517238","title":"Intra-Cellular Therapies Presents Data from the CAPLYTA Adjunctive MDD Phase 3 Program at the American College of Neuropsychopharmacology Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2490517238","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490517238?lang=en_us&edition=fundamental","pubTime":"2024-12-11 21:00","pubTimestamp":1733922000,"startTime":"0","endTime":"0","summary":"Presentations complement topline data with new data from two pivotal studies (Studies 501 and 502) evaluating lumateperone as an adjunctive therapy for the treatment of major depressive disorder Data ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/11/2995339/30597/en/Intra-Cellular-Therapies-Presents-Data-from-the-CAPLYTA-Adjunctive-MDD-Phase-3-Program-at-the-American-College-of-Neuropsychopharmacology-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","IE00BMG7P819.SGD","IE00BZ18W456.USD","BK4081","LU0053671581.USD","LU0109394709.USD","AFG","LU1880398471.USD","LU0106261612.USD","LU0889565916.HKD","IE00BMQBXF63.USD","BK4117","ABVC","LU2449327464.USD","LU2637428348.USD","LU1883839398.USD","ADT","BK4165","IE00B29SXL02.USD","BK4585","IE00BMG7P926.USD","ITCI","LU1803068623.USD","BK4107","IE00BMG7P694.USD","CNS","IE00B29SXK94.USD","LU0012050646.USD","BK4007","NMS","LU1880398554.USD","BK4135","ES","IE00BMG7P587.USD","BK4192","IE00BZ18W340.USD","LU0320765992.SGD","BK4139"],"gpt_icon":0},{"id":"2490830205","title":"BRIEF-ABVC Biopharma Secures $200,000 In First Cash Licensing Payment From Oncology Products Partner","url":"https://stock-news.laohu8.com/highlight/detail?id=2490830205","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490830205?lang=en_us&edition=fundamental","pubTime":"2024-12-11 19:32","pubTimestamp":1733916724,"startTime":"0","endTime":"0","summary":"BRIEF-ABVC Biopharma Secures $200,000 In First Cash Licensing Payment From Oncology Products PartnerDec 11 (Reuters) - ABVC Biopharma Inc ABVC.O:ABVC BIOPHARMA SECURES $200,000 IN FIRST CASH LICENSING","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241211:nTUA5298WX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ABVC"],"gpt_icon":0},{"id":"2490830290","title":"ABVC Biopharma Inc - Receives $200,000 Payment From Oncox Biopharma","url":"https://stock-news.laohu8.com/highlight/detail?id=2490830290","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490830290?lang=en_us&edition=fundamental","pubTime":"2024-12-11 19:30","pubTimestamp":1733916600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241211:nTUA5298WX:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ABVC"],"gpt_icon":0},{"id":"2490302138","title":"ABVC Biopharma Secures $200,000 in First Cash Licensing Payment From Oncology Products Partner, Totaling $546,000 From Three Partners","url":"https://stock-news.laohu8.com/highlight/detail?id=2490302138","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490302138?lang=en_us&edition=fundamental","pubTime":"2024-12-11 19:30","pubTimestamp":1733916600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241211:nTUA5298WX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ABVC"],"gpt_icon":0},{"id":"2490830052","title":"ABVC BioPharma Secures $200,000 in First Cash Licensing Payment From Oncology Products Partner, Totaling $546,000 From Three Partners","url":"https://stock-news.laohu8.com/highlight/detail?id=2490830052","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490830052?lang=en_us&edition=fundamental","pubTime":"2024-12-11 19:30","pubTimestamp":1733916600,"startTime":"0","endTime":"0","summary":"FREMONT, Calif., Dec.  11, 2024  (GLOBE NEWSWIRE) -- ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company advancing therapeutic solutions in ophthalmology, CNS (central nerv","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/11/2995223/0/en/ABVC-BioPharma-Secures-200-000-in-First-Cash-Licensing-Payment-From-Oncology-Products-Partner-Totaling-546-000-From-Three-Partners.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["WRD","ABVC","BK4139","BK4166","FCFS","PHH"],"gpt_icon":0},{"id":"2490014346","title":"Neuronetics and Greenbrook TMS Announce Closing of Transaction","url":"https://stock-news.laohu8.com/highlight/detail?id=2490014346","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490014346?lang=en_us&edition=fundamental","pubTime":"2024-12-10 23:00","pubTimestamp":1733842800,"startTime":"0","endTime":"0","summary":"MALVERN, Pa. and TORONTO, Dec.  10, 2024  (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (“Neuronetics”) and Greenbrook TMS Inc. (OTCMKTS: GBNHF) (“Greenbrook”, and together with Neuronetics, th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/10/2994694/0/en/Neuronetics-and-Greenbrook-TMS-Announce-Closing-of-Transaction.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","STIM","WRD","BK4082","ABVC","PHH"],"gpt_icon":0},{"id":"2490011816","title":"Cybin Announces Poster Presentations at the 2024 American College of Neuropsychopharmacology Annual Meeting, Including CYB003 12-Month Efficacy Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2490011816","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490011816?lang=en_us&edition=fundamental","pubTime":"2024-12-10 20:30","pubTimestamp":1733833800,"startTime":"0","endTime":"0","summary":"- Poster presentations highlight clinical data across Cybin’s CYB003 deuterated psilocin and DMT programs -. \"The ACNP annual meeting is an excellent opportunity to share the rapid clinical progress Cybin is making across our deuterated psilocin and DMT programs,\" said Doug Drysdale, Chief Executive Officer of Cybin. \"MDD affects roughly 21 million people in the U.S., alone, yet roughly two thirds do not experience relief from traditional antidepressant treatments. Developing new and improved treatments for MDD sufferers is a top priority for us. We look forward to engaging with the internationally distinguished researchers and scientists who share our passion to bring innovative therapeutics to the mental health space. With the recent initiation of our Phase 3 PARADIGM program evaluating CYB003 in MDD, this is a pivotal time for Cybin,\" concluded Drysdale. \"In addition to our CYB003 program, Cybin is advancing our deuterated DMT program, CYB004, which is currently in a Phase 2 General","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/lZ8GyFRM.GVp_M5etWmodg--~B/aD0yNjg7dz00NjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/285d90530d9c6a9223323463df832395","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/lZ8GyFRM.GVp_M5etWmodg--~B/aD0yNjg7dz00NjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/285d90530d9c6a9223323463df832395"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cybin-announces-poster-presentations-2024-123000178.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4007","CYBN","AFG","BK4117","BK4107","BK4168","ABVC"],"gpt_icon":0},{"id":"2489268188","title":"J&J trial news may have positive read for Neumora Therapeutics, says RBC Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2489268188","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489268188?lang=en_us&edition=fundamental","pubTime":"2024-12-07 03:30","pubTimestamp":1733513419,"startTime":"0","endTime":"0","summary":"RBC Capital analyst Brian Abrahams notes that the clinicaltrials.gov listing for Johnson & Johnson’s (JNJ) second MDD Phase 3 trial with aticaprant...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/jj-trial-news-may-have-positive-read-for-neumora-therapeutics-says-rbc-capital?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/jj-trial-news-may-have-positive-read-for-neumora-therapeutics-says-rbc-capital?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0058720904.USD","LU0098860793.USD","BK4533","IE00BGHQF631.EUR","BK4592","LU0345769631.USD","LU1032955483.USD","LU2133065610.SGD","LU1244550577.SGD","LU0203347892.USD","LU1674673428.USD","LENZ","LU1023059063.AUD","LU1674673691.USD","LU1718418525.SGD","BK4585","LU0795875169.SGD","IE00BFTCPJ56.SGD","IE00B7SZLL34.SGD","LU1066051811.HKD","LU1585245621.USD","NMRA","IE0002141913.USD","LU1244550494.USD","IE00BSNM7G36.USD","IE00B3PB1722.GBP","LU2089984988.USD","LU0792757196.USD","IE00BJT1NW94.SGD","LU0345769128.USD","LU1506573853.SGD","IE00BDGV0183.EUR","BK4559","IE00B19Z3B42.SGD","LU1244550221.USD","LU1162221912.USD","LU1914381329.SGD","LU0234570918.USD","JNJ","LU2468319806.SGD","SG9999002232.USD","ABVC","LU1267930813.SGD","LU0122379950.USD","LU1935042991.SGD","IE00BJJMRZ35.SGD","IE00BVYPNV92.GBP","BK4581","LU0912757837.SGD"],"gpt_icon":0},{"id":"2489434143","title":"ITCI Submits sNDA to the FDA for Expanded Use of Caplyta in MDD","url":"https://stock-news.laohu8.com/highlight/detail?id=2489434143","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489434143?lang=en_us&edition=fundamental","pubTime":"2024-12-05 01:00","pubTimestamp":1733331600,"startTime":"0","endTime":"0","summary":"Intra-Cellular TherapiesITCI announced that it has submitted a supplemental new drug application  to theFDA aiming to expand the approved uses of its lead drug, Caplyta , to include treating major depressive disorder  in adults as an adjunctive therapy to antidepressants.The sNDA submission is supported by positive results from two late-stage studies, Studies 501 and 502, that evaluated 42 mg of lumateperone as an adjunctive therapy to antidepressants for MDD. Both studies met the primary and key secondary efficacy endpoints, demonstrating Caplyta’s robust antidepressant efficacy and favorable safety and tolerability profile.Subject to its approval for the MDD indication, Caplyta would be indicated for the treatment of three different major psychiatry indications affecting more than 30 million adult patients in the United States. In the past three months, shares of Intra-Cellular have gained 17.8% against the industry’s 5.1% decline.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/ecFYZtqvCgQ1G__HXA8vTQ--~B/aD0zNDM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/00e8f1a41a7bc7b2ecf8d421f3c6f574","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/ecFYZtqvCgQ1G__HXA8vTQ--~B/aD0zNDM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/00e8f1a41a7bc7b2ecf8d421f3c6f574"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/itci-submits-snda-fda-expanded-170000000.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4578","LU0106261612.USD","BK4007","IE0002270589.USD","IE000M9KFDE8.USD","LU1883839398.USD","LU0321505868.SGD","SG9999001176.SGD","BK4550","IE00B19Z3581.USD","BK4588","IE00BKVL7J92.USD","ITCI","LU0058720904.USD","LU0234572021.USD","LU2087621335.USD","LU0306807586.USD","BK4505","SG9999002224.SGD","ALLO","LU1571399168.USD","CNS","IE00BZ1G4Q59.USD","LU0170899867.USD","IE00BLSP4452.SGD","BK4568","ABVC","SG9999013999.USD","LU0456855351.SGD","LU0868494617.USD","GILD","BK4135","LU0012050646.USD","IE00B3T34201.USD","LU1585245621.USD","IE00BBT3K403.USD","LU0321505439.SGD","LU1023059063.AUD","BK4566","PFE","LU0234570918.USD","LU0053671581.USD","SGXZ57979304.SGD","IE00BSNM7G36.USD","IE00B7SZLL34.SGD","LU1057294990.SGD","BK4592","LU0320765992.SGD","LU0985481810.HKD","LU0889565916.HKD"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.abvcpharma.com","stockEarnings":[{"period":"1week","weight":0.0376},{"period":"1month","weight":-0.0765},{"period":"3month","weight":-0.2468},{"period":"6month","weight":-0.2651},{"period":"1year","weight":-0.5236},{"period":"ytd","weight":-0.5483}],"compareEarnings":[{"period":"1week","weight":-0.0216},{"period":"1month","weight":0.0011},{"period":"3month","weight":0.0403},{"period":"6month","weight":0.0857},{"period":"1year","weight":0.2506},{"period":"ytd","weight":0.2437}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.067297},{"month":2,"riseRate":0,"avgChangeRate":-0.074163},{"month":3,"riseRate":0.666667,"avgChangeRate":0.008224},{"month":4,"riseRate":0.333333,"avgChangeRate":0.005269},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.062733},{"month":6,"riseRate":0.166667,"avgChangeRate":1.432014},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.126621},{"month":8,"riseRate":0.428571,"avgChangeRate":-0.087867},{"month":9,"riseRate":0.285714,"avgChangeRate":-0.085669},{"month":10,"riseRate":0.428571,"avgChangeRate":-0.065345},{"month":11,"riseRate":0.714286,"avgChangeRate":0.0634},{"month":12,"riseRate":0.428571,"avgChangeRate":-0.001152}],"exchange":"NASDAQ","name":"ABVC BioPharma, Inc.","nameEN":"ABVC BioPharma, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ABVC BioPharma, Inc.(ABVC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest ABVC BioPharma, Inc.(ABVC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"ABVC BioPharma, Inc.,ABVC,ABVC BioPharma, Inc.股票,ABVC BioPharma, Inc.股票老虎,ABVC BioPharma, Inc.股票老虎国际,ABVC BioPharma, Inc.行情,ABVC BioPharma, Inc.股票行情,ABVC BioPharma, Inc.股价,ABVC BioPharma, Inc.股市,ABVC BioPharma, Inc.股票价格,ABVC BioPharma, Inc.股票交易,ABVC BioPharma, Inc.股票购买,ABVC BioPharma, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ABVC BioPharma, Inc.(ABVC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest ABVC BioPharma, Inc.(ABVC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction